Renaissance Technologies’s Kyverna Therapeutics KYTX Stock Holding History

Renaissance Technologies’s Portfolio KYTX Stock Details KYTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.23M	Sell	327,821 -6,078	-2%	-$48K	﹤0.01%	1892
2026 Q2	$2.98M	Sell	333,899 -33,593	-9%	-$298K	﹤0.01%	1745
2026 Q1	$3.17M	Buy	367,492 +189,593	+107%	+$1.58M	0.01%	1636
2025 Q4	$1.67M	Buy	177,899 +13,285	+8%	+$98.6K	﹤0.01%	1977
2025 Q3	$988K	Buy	164,614 +42,197	+34%	+$169K	﹤0.01%	2489
2025 Q2	$376K	Sell	122,417 -2,541	-2%	-$6.28K	﹤0.01%	2968
2025 Q1	$241K	Buy	124,958 +80,258	+180%	+$237K	﹤0.01%	3009
2024 Q4	$167K	Buy	+44,700	New	+$214K	﹤0.01%	3209

Other funds holding KYTX

Gilead Sciences Foster City, California $1.46B AUM 71.23% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return

Renaissance Technologies's KYTX Position: Q3 2026 in Review

Renaissance Technologies reduced its Kyverna Therapeutics (KYTX) stake by 1.8% in Q3 2026, selling an estimated $48K and leaving 327,821 shares worth $2.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1892.

Renaissance Technologies first reported a position in KYTX in Q4 2024 and has held it in 8 quarters since. The position peaked at $3.17M in Q1 2026. 64 funds tracked by Wall St. Rank hold KYTX as of Q3 2026.

Renaissance Technologies held 327,821 shares of Kyverna Therapeutics worth $2.23M as of Q3 2026.
Renaissance Technologies sold 6,078 Kyverna Therapeutics shares in Q3 2026, an estimated $48K.
Kyverna Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q3 2026, its #1892 holding.
Renaissance Technologies first reported a position in Kyverna Therapeutics in Q4 2024 and has held it in 8 quarters since.
Renaissance Technologies's Kyverna Therapeutics position peaked at $3.17M in Q1 2026.
64 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q3 2026.

Based on Renaissance Technologies's 13F filing for Q3 2026, filed 12 Nov 2026.